Menveo: side effects, ingredients & package insert

Menveo ingredients (FDA package insert, Section 11)

Per-dose composition as stated in the prescribing information; verified 2026-07-09. Click an ingredient for every vaccine that contains it.

Source: FDA package insert. Formulations change — re-verify before clinical use.

Menveo side effects: where the data is

Reported reactions for Menveo and the other meningococcal products are compiled on the meningococcal vaccine page: pre-licensure trial reactogenicity, VAERS report counts, and international databases (Canada Vigilance, EudraVigilance, Lareb, VigiAccess). Those counts are spontaneous reports with no denominator — a report does not establish that the vaccine caused the event.

• Pre-licensure clinical trial data
• Post-licensure surveillance (VAERS and international)
• Documented adverse events and causality assessment
• Vaccine Injury Table (VICP) — compensable injuries

Menveo lot number lookup

Menveo vs Bexsero

All licensed meningococcal vaccine products side by side. Differences in platform, adjuvant and route are the usual reasons one is chosen over another; efficacy and safety comparisons belong to the trial and surveillance sections of the meningococcal vaccine page.

Schedule and age range

Licensed ages and the recommended series for meningococcal vaccines are on the meningococcal vaccine page; how 31 countries schedule it is on meningococcal schedule by country. Always confirm the product-specific age range in the current package insert.

Common questions about Menveo

What are the side effects of Menveo?

Common reactions listed in the Menveo package insert are injection-site pain, redness or swelling and short-lived systemic symptoms such as fever, tiredness or irritability. Rarer events and the reported counts from VAERS and international databases are on the meningococcal vaccine page; counts are reports, not rates, and do not prove the vaccine caused the event.

What is in Menveo?

Menveo contains Neisseria meningitidis serogroup A polysaccharide-CRM197 conjugate; Serogroup C polysaccharide-CRM197 conjugate; Serogroup W-135 polysaccharide-CRM197 conjugate; Serogroup Y polysaccharide-CRM197 conjugate as antigen; adjuvant: none; it is preservative-free. Excipients: Potassium dihydrogen phosphate, Sucrose, Sodium chloride, Sodium dihydrogen phosphate monohydrate / dibasic. Amounts per dose are in the table above, taken from Section 11 of the FDA package insert (verified 2026-07-09).

Where is the Menveo package insert?

The FDA-licensed prescribing information for Menveo is published by GlaxoSmithKline Biologicals and the FDA; the source used for this page is https://www.fda.gov/vaccines-blood-biologics/vaccines/menveo. Formulations change, so re-verify the current insert before clinical use.

How does Menveo compare with Bexsero?

Menveo (GlaxoSmithKline Biologicals) uses a conjugate platform with adjuvant none, given intramuscular; Bexsero (GlaxoSmithKline Biologicals) uses subunit with adjuvant Aluminum hydroxide. Both are licensed meningococcal vaccines; the comparison table above lists every product.